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With the rapidly growing and aging world
population comes an urgent and rising
demand for new and better drugs. Many
observers feel that the pharmaceutical
industry seems unable to satisfy this de-
mand. Although the industry’s investment
in research and development has steadily
increased, from about $16 billion in 1993
to nearly $60 billion in 2007, the number
of new molecules and biologics approved
each year has remained almost un-
changed. The past few decades have pro-
duced a dazzling array of high-throughput
life science technologies such as geno-
mics, proteomics, and mass spectrometry
that have dramatically increased the num-
ber of ‘‘druggable’’ targets. Unfortunately,
this has not yet translated into a flood of
new remedies. Indeed, as the US Govern-
ment Accountability Office points out, until
now such technologies have resulted only
in ‘‘increasing expenses without a com-
mensurate increase in the number of
drugs developed.’’
According to industry estimates, bring-
ing out a new drug typically takes up to 15
years and costs $1 billion or more. Failure
rates remain high: only 1 or 2 compounds
out of 10,000 tested make it to the market.
Many drugs may go through 75–100 clin-
ical trials and often fail at the later stages
after considerable resources have already
been spent on them. ‘‘The efficiency of
drug development is low,’’ says Carl Peck,
the founding director of the Center for
Drug Development Science at the Univer-
sity of California, San Francisco (UCSF). A
former director of the Center for Drug
Evaluation and Research at the FDA, Peck
believes that the wider use of in silico
modeling and simulation methods could
help improve this situation. Sean Ekins,
a clinical pharmacologist and editor of
a recent book on computer applications
in pharmaceutical research and develop-
ment, agrees. ‘‘The combination of chem-
istry and biology with informatics has led
to advances in silico pharmacology,’’ he
says. ‘‘In silico methods can now simulate
practically every aspect of drug discovery
and development.’’
The use of quantitative methods in
pharmacology dates back to the late
19th century, when relations between
physical and chemical properties of com-
pounds and their biological activities were
first studied. Decades later, in the 1960s,
Corwin Hansch and other scientists
began to establish so-called quantitative
structure-activity relationships (QSARs)
tying various molecular descriptors to
physical, chemical, and biological pro-
perties. This effort still continues, and
the public domain ‘‘C-QSAR’’ database,
which now contains thousands of such
models, has become a valuable resource
for drug discovery. In the 1980s and 90s,
advances in computer technology led to
a number of in silico techniques for mod-
eling ligand-target interactions. Such
drug discovery techniques have rapidly
grown in speed and power. ‘‘You can now
run all your molecules of interest simulta-
neously against different computational
models of targets and antitargets,’’ says
Ekins. ‘‘This was a pipe dream a decade
ago, but it is reality now.’’
To find new lead compounds, a conven-
tional in vitro high-throughput screening
assay will typically test a library of up to
a million compounds against the target
of interest. Besides being expensive and
cumbersome, such large-scale assays
sometimes miss valid leads and/or give
false matches. Fortunately, many virtual
screening techniques have now become
available as a complement or alternative.
A well-known example is the DOCK soft-
ware from UCSF, which uses information
about molecular structure to predict how
well a ligand will bind to a target. In
2002, researchers at Pharmacia Corpora-
tion (now part of Pfizer) used this and
other computer tools to match a library
of 235,000 compounds with protein tyro-
sine phosphatase-1B, an enzyme impli-
cated in diabetes. The search yielded
365 high-scoring molecules. Subsequent
in vitro testing showed that 127 of these
inhibited the enzyme effectively – a hit
rate of nearly 35%. Traditional high
throughput screening, in contrast, gave
a hit rate of just over 0.02%. Interestingly,
the two ‘‘hit lists’’ differed significantly: the
hits from virtual screening appeared more
‘‘drug-like’’ than the ones from real
screening (Doman et al., 2002).
Another validation of the in silico ap-
proach to drug screening came in 2003.
Research groups at two companies had
both been on the hunt for a small-mole-
cule inhibitor for the TGFb-1 receptor ki-
nase, a protein that helps form actin fibers
in cells and tissues. Of major interest in
cancer research, this protein is also impli-
cated in other fibrotic conditions such as
ocular scarring. The first group, at Eli Lilly,
found an inhibitor using conventional
‘‘wet-lab’’ assays. The other group, at
Biogen Idec, chose to go with an in silico
approach. It used software from San
Diego-based Accelrys to build a ligand
model based on a known weak inhibitor
of the kinase and then searched a com-
puter database of 200,000 compounds
for similar molecules. The search yielded
87 hits; the most promising of these
turned out to be identical to Eli Lilly’s mol-
ecule (Sawyer et al., 2003; Singh et al.,
2003, 2004). ‘‘That was a perfect example
of how you could come up with a lead
molecule without having to synthesize it,’’
says Shikha Varma-O’Brien, an associate
director at Accelrys. ‘‘This capability is of
tremendous importance to chemists.’’
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covery, in silico methods for drug devel-
opment began to emerge in the 1970s.
‘‘Prior to the 70s, much of drug develop-
ment was empirical and sloppy,’’ recalls
Peck. Researchers began to use com-
putational methods to model the inter-
actions between drugs and biological
systems: the so-called pharmacokinetic
and pharmacodynamic processes. Since
then, computational tools relevant to
drug development have grown in scope
and sophistication. Biological systems
that can now be modeled in silico range
from a single pathway or disease to entire
cells, organs, patients, populations, or
even clinical trials. Other tools help re-
searchers navigate and mine the vast
amounts of information in the various
genetic, genomic, proteomic, and other
biology databases to build these models.
‘‘Over the years, there has been a para-
digm shift at the FDA towards greater
use of these technologies,’’ says Peck.
‘‘The agency has been encouraging the
drug industry to use them as well.’’
Several companies now specialize in
developing innovative computational
tools for drug development. Adding new
meaning to the term ‘‘computer mouse,’’
Foster City, California, based Entelos
offers researchers in type 1 diabetes their
favorite tool, the immune system of a non-
obese diabetic mouse—built entirely in
silico. Developed in collaboration with
the American Diabetes Association, the
virtual mouse immune system is far easier
to manipulate than its flesh-and-blood
counterpart. As a versatile and inexhaust-
ible resource, this in silico animal model
could open new avenues for diabetes
research, says Richard Kahn, the diabetes
association’s chief scientific and medical
officer. ‘‘There are many questions in dia-
betes that we may never resolve using
clinical trials,’’ says Kahn. ‘‘Maybe mathe-
matical models could provide effective
and accurate answers.’’
Entelos uses a top-down approach to
construct disease platforms and virtual
patient populations, drawing from clinical
trial results, pathway databases, and
other results from the literature. ‘‘We build
mechanistic models in a compartmental
way and then add granularity to those
compartments and integrate them ac-
cording to the question being asked’’
says Mikhail Gishizky, the company’s414 Chemistry & Biology 15, May 2008 ª200chief scientific officer. ‘‘We don’t need to
take the modeling down to the gene level
in every area.’’ Richard Ho, a principal at
La Jolla, California, based Rosa, supports
this principle. ‘‘Stuff that happens at the
cellular level often doesn’t make it to clin-
ical significance,’’ he says. In his previous
tenure as a diabetes researcher at John-
son & Johnson, Ho used software from
Entelos to show that an experimental dia-
betes drug, which another company had
successfully tested on animal models,
would fail in humans. Meanwhile, the other
company went ahead with clinical trials
for this drug. Two years later the results
of the trial were in: the drug was ineffec-
tive. ‘‘The results looked exactly like what
we’d predicted with our models,’’ says Ho.
‘‘That’s lots of time, effort, and expense
we saved with four months of computer
modeling.’’
Taking a different tack, Cambridge,
Massachusetts, based Gene Network
Sciences uses massively parallel com-
puters to ‘‘reverse-engineer’’ disease
models directly from gene chip and other
high-throughput data. This data-driven
approach is particularly effective at cap-
turing the effect of genetic and genomic
variations, says the company’s executive
vice president and co-founder Iya Khalil.
She mentions results of unpublished
study where researchers used the com-
pany’s software to reverse-engineer and
simulate the action of a cancer drug;
among the genes that the simulation de-
tected as being important for the drug’s
efficacy were several that were not previ-
ously known to affect the drug’s pathway
(Pitluk and Khalil, 2007). ‘‘Using this sys-
tem, you can test millions of hypotheses
and then go back and see where these
predictions fall in the context of the litera-
ture,’’ says Khalil. ‘‘Often you end up
discovering new biology relevant for the
efficacy of the drug.’’
The list of companies developing in sil-
ico tools for pharmacology has steadily
grown during the past two decades. This
proliferation of tools and vendors has
brought its own challenges, such as in-
compatible data formats, which some
newer platforms are trying to address.
Meanwhile, at the big pharmaceutical
firms, the intended clients for these prod-
ucts, interest in in silico methods is grow-
ing. Most of these companies are now
either developing such methods in house8 Elsevier Ltd All rights reservedor working with partners that provide
them. The FDA, too, is collaborating with
many in silico tool developers including
Entelos, UK-based SymCyp, and Moun-
tain View, California, based Pharsight.
‘‘In silico methods are having an increas-
ingly important role in different areas of
pharmaceutical research and develop-
ment,’’ says Ekins.
Will computational methods ever be
able to completely replace in vitro and in
vivo testing? ‘‘The answer here can only
be a clear and resounding ‘no’, at least in
the near future,’’ says Ekins, along with co-
authors Jordi Mestres and Bernard Testa
in a pair of recent review articles (Ekins
et al., 2007a, 2007b). They point out that
biological systems have a highly nonlin-
ear, even chaotic nature, whereby even
tiny changes in initial conditions could
make them behave in a dramatically differ-
ent manner. ‘‘No computer program will
ever be able to fully model their complex-
ity,’’ they argue. Peck is more optimistic.
‘‘There may come a time, perhaps 50 or
100 years in the future, when drugs will
be discovered in silico, tested in silico, op-
timized in silico, and made available to
patients for clinical use with little or no con-
firmatory testing,’’ he says. ‘‘This is a bold
and even somewhat frightening vision, but
someday we’ll know enough about biol-
ogy to go a long way towards this goal.’’
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